Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive randomized double-blind placebo-controlled trial of anti-SARS-CoV-2 hyperimmune intravenous immunoglobulin in hospitalized adults with early progressive COVID-19
MOH_2020-11-16_009511Phase 3Not yet recruiting
- Sponsor
- דר' דן טורנר
- Start
- Nov 2020
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of CoviGlobulin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by דר' דן טורנר. Planned start Nov 2020; status: not yet recruiting.
02
Drugs
CoviGlobulin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on MOH_2020-11-16_009511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-11-16_009511.